Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 144 of the 145 references it cites were found in a registry or an index.

Non-alcoholic fatty liver disease

Abstract

Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% and is a leading cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a disease continuum from steatosis with or without mild inflammation (non-alcoholic fatty liver), to non-alcoholic steatohepatitis (NASH), which is characterised by necroinflammation and faster fibrosis progression than non-alcoholic fatty liver. NAFLD has a bidirectional association with components of the metabolic syndrome, and type 2 diabetes increases the risk of cirrhosis and related complications. Although the leading causes of death in people with NAFLD are cardiovascular disease and extrahepatic malignancy, advanced liver fibrosis is a key prognostic marker for liver-related outcomes and overall mortality, and can be assessed with combinations of non-invasive tests. Patients with cirrhosis should be screened for hepatocellular carcinoma and oesophageal varices. There is currently no approved therapy for NAFLD, although several drugs are in advanced stages of development. Because of the complex pathophysiology and substantial heterogeneity of disease phenotypes, combination treatment is likely to be required for many patients with NAFLD. Healthy lifestyle and weight reduction remain crucial to the prevention and treatment of NAFLD.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)32511-3

Cites

144 of 144 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 145 references

Cited by

See all 2,789

Metadata

Authors
Powell, E. E., Wong, V. W.-S., & Rinella, M.
Affiliations
  • Translational Research Institute (AU)
  • Chinese University of Hong Kong (HK)
  • Northwestern University (US)
Corresponding author
Powell, Elizabeth E
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-06
Volume
397
Issue
10290
Pages
2212-2224
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3154897461
Cited by
2,789
References
145
Citations by year
2026: 418 · 2025: 654 · 2024: 768 · 2023: 610 · 2022: 291 · 2021: 48
FWCI
66.42
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
Novartis
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, liver fibrosis, liver cirrhosis, hepatocellular carcinoma, metabolic syndrome, type 2 diabetes, cardiovascular disease, noninvasive fibrosis assessment, NAFLD therapy, lifestyle intervention, weight loss, disease progression
MeSH terms
Diabetes Mellitus, Type 2, Carcinoma, Hepatocellular, Humans, Liver Cirrhosis, Liver Neoplasms, Disease Progression, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non-alcoholic fatty liver disease. https://app.cochat.ai/papers/10.1016/s0140-6736(20)32511-3
The paper
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021). Non-alcoholic fatty liver disease. The Lancet. https://doi.org/10.1016/s0140-6736(20)32511-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.